AAAAAA

   
Results: 1-8 |
Results: 8
Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor
Authors: Gianotti, N Tambussi, G Boeri, E Lazzarin, A
Citation: N. Gianotti et al., Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor, J BIOL REG, 15(2), 2001, pp. 166-169
Acute self-limiting hepatitis C after possible sexual exposure: Sequence analysis of the E-2 region of the infected patient and sexual partner
Authors: Morsica, G Sitia, G Bernardi, MT Tambussi, G Novati, R De Bona, A Gianotti, N Lazzarin, A
Citation: G. Morsica et al., Acute self-limiting hepatitis C after possible sexual exposure: Sequence analysis of the E-2 region of the infected patient and sexual partner, SC J IN DIS, 33(2), 2001, pp. 116-120
Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy
Authors: Tambussi, G Ghezzi, S Nozza, S Vallanti, G Magenta, L Guffanti, M Brambilla, A Vicenzi, E Carrera, P Racca, S Soldini, L Gianotti, N Murone, M Veglia, F Poli, G Lazzarin, A
Citation: G. Tambussi et al., Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy, J INFEC DIS, 183(10), 2001, pp. 1476-1484
Hepatitis B surface antigen clearance and appearance of antibodies againsthepatitis B surface antigen after treatment with recombinant interleukin 2in a human immunodeficiency virus-infected patient
Authors: Gianotti, N Uberti-Foppa, C Boeri, E Marinelli, M Tambussi, G Finazzi, R Lazzarin, A
Citation: N. Gianotti et al., Hepatitis B surface antigen clearance and appearance of antibodies againsthepatitis B surface antigen after treatment with recombinant interleukin 2in a human immunodeficiency virus-infected patient, HEPATOLOGY, 32(6), 2000, pp. 1409-1410
Study on mutations and antiretroviral therapy (SMART): preliminary results
Authors: Gianotti, N Moretti, F Tambussi, G Racca, S Presi, S Crucianelli, R Carrera, P Ferrari, M Lazzarin, A
Citation: N. Gianotti et al., Study on mutations and antiretroviral therapy (SMART): preliminary results, ANTIVIR TH, 4, 1999, pp. 65-69
The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs
Authors: Gianotti, N Moretti, F Tambussi, G Capiluppi, B Ferrari, M Lazzarin, A
Citation: N. Gianotti et al., The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs, J BIOL REG, 13(3), 1999, pp. 158-162
Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients
Authors: Uberti-Foppa, C De Bona, A Morsica, G Guffanti, M Gianotti, N Boeri, E Lazzarin, A
Citation: C. Uberti-foppa et al., Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients, AIDS, 13(1), 1999, pp. 140-141
SMART - study on mutations and antiretroviral therapy: preliminary results
Authors: Gianotti, N Moretti, F Tambussi, G Nozza, S Ciuffreda, D Lazzarin, A Racca, S Boeri, E Crucianelli, R Ferrari, M Moroni, M Angarano, G Sinicco, A
Citation: N. Gianotti et al., SMART - study on mutations and antiretroviral therapy: preliminary results, SEVENTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION, 1999, pp. 87-91
Risultati: 1-8 |